STUDY Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor

evaluate the incidence and severity of cutaneous reac-tions induced by sorafenib tosylate, a new oral multiki-nase inhibitor. Design: Double-blind, prospective dermatologic sub-study performed on all consecutive patients included in our center in a large phase 3 trial. Setting: Institutional practice at the Gustave Roussy In-stitute. Patients:Eighty-five patientswith renal cell cancer treate